Physician profile
David Schaumberger
NPI 1093771339
$1,675.71
in general payments reported to CMS, 2019-2025
15 companies · $392 in 2025
The $392 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $15.00 · 2021: $72.32 · 2022: $230 · 2023: $253 · 2024: $295 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.14 | 2019-2025 | Bexsero |
| Merck Sharp & Dohme LLC | $257.45 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $247.35 | 2019-2025 | |
| Kaleo, INC. | $202.55 | 2019-2024 | Auvi-Q |
| Galderma Laboratories, L.P. | $163.17 | 2019 | |
| Pfizer INC. | $103.88 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $98.78 | 2024-2025 | |
| Sobi, INC | $57.62 | 2019-2024 | |
| Seqirus USA INC | $55.00 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $35.47 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $31.86 | 2024 | Flumist Quadrivalent |
| Bavarian Nordic A/S | $17.11 | 2025 | Vivotif |
| Alexion Pharmaceuticals, INC. | $14.41 | 2022 | |
| Neos Therapeutics, LP | $14.22 | 2023 | Adzenys Xr-Odt |
| Aytu Biopharma, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schaumberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.